



MARKET RELEASE

15 June 2017

Paradigm Biopharmaceuticals Ltd

TRADING HALT

The securities of Paradigm Biopharmaceuticals Ltd (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Monday, 19 June 2017 or when the announcement is released to the market.

Security Code: PAR

Kobe Li

SENIOR ADVISER, LISTINGS COMPLIANCE (MELBOURNE)



15 June 2017

By email: zheng.li@asx.com.au

ASX Compliance Pty Limited
Level 4 North Tower
525 Collins Street
Melbourne VIC 3000

Dear Kobe

Request for a trading halt

Paradigm Biopharmaceuticals Ltd ACN 169 346 963 (ASX: PAR) (the **Company**), requests that the Company's securities be placed into trading halt with immediate effect.

Pursuant to ASX Listing Rule 17.1, the Company requests the trading halt in order for the Company to review the status of its current clinical trial in allergic rhinitis - which the Company is not in a position to announce to the market at present.

We anticipate that the trading halt will be required until no later than 10am on 16 June 2017. An announcement will be made to the market prior to that time which will clarify the above.

The Company is not aware of any reason why the trading halt should not be granted by the ASX.

Please contact us should you have any questions.

Yours faithfully

Kevin Hollingsworth
Company Secretary

Paradigm BioPharmaceuticals Ltd
C/- Hollingsworth & Co Pty Ltd, Level 2, 517 Flinders Lane, Melbourne, VIC, 3000, AUSTRALIA
ABN: 94 169 346 963
Web: <http://paradigmbiopharma.com/>